Management of Osteoporosis
Key Points
Key Points
- Patients with non-metastatic cancer may be at risk for osteoporotic fractures due to baseline risks or due to the added risks associated with their cancer therapy.
- Clinicians are advised to assess fracture risk using established tools.
- For those with substantial risk of osteoporotic fracture the clinician should obtain a bone mineral density.
- The bone health of all patients may benefit from optimizing nutrition, exercise and lifestyle.
- When a pharmacologic agent is indicated, bisphosphonates or denosumab, at osteoporosis-indicated dosages, are the preferred interventions.
Assessment
...essment...
...isk
....1. It is recommended that patients with non-...
...mendation 1.2. Clinicians should be awar...
...ation 1.3. Clinicians may use a ris...
...creening
...dation 2.1. Patients with non-metastatic cancer...
....2. Patients with non-metastatic cancer who are...
Treatment
Treatme...
...-pharmacological Intervention
...mendation 3.1. Clinicians should encou...
....2. Clinicians should actively encourage patient...
...ation 3.3. Clinicians should actively encourage...
...macological Interve...
....4. For patients with non-metastatic cancer with o...
...on 3.5. Provided T-score and/or risk assessmen...
...1. Algorithm for Maintaining Bone...
...able 1. Osteoporotic Fracture Risk...
...e Loss Associated with Various Cancer Thera...
...ble 3. Commonly used Bone Modifying Agent...
...ed Drug Costs for Bone Modifying Ag...